Recent Quotes (30 days)

You have no recent quotes
chg | %

Healthcare News

Showing stories 1 - 10 of about 70   
Better Buy: Johnson & Johnson vs. Merck
J&J stock is up in 2017, while Merck is down. But could the roles be reversed in 2018 and beyond? Keith Speights. (TMFFishBiz).
These stocks would serve your income portfolio better than Johnson & Johnson ...
Shares of medical products veteran Johnson & Johnson (NYSE:JNJ) come with a household name, decades of proven success, and a 2.4% dividend yield.
ASH: Johnson & Johnson scores big Darzalex win in first-line myeloma, slashing ...
ATLANTA—Johnson & Johnson's Janssen unit has found plenty of success moving Darzalex earlier and earlier into multiple myeloma therapy, and it now has data that could help it win a coveted spot in first-line treatment.
The Outlook For Johnson & Johnson's Immunology Drug Business
Johnson & Johnson's immunology portfolio, which primarily consists of Remicade, Simponi and Stelara, accounts for around 15% of the company's value, according to our estimates.
As Johnson & Johnson holds off US biosims, Remicade's European ...  FiercePharma
Pfizer Inc. Announces Expiration and Results of its Private Exchange Offer for ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) (“Pfizer”) today announced the expiration and results of its previously announced offers to exchange and to repurchase any and all of its outstanding �1,500,000,000 6.500 per cent.
Johnson & Johnson ordered to pay $15M in vaginal mesh case
A Johnson & Johnson subsidiary was ordered Thursday to pay $15 million in damages to a New Jersey woman who was left in chronic pain after receiving defective transvaginal mesh implants.
Why 2017 Was a Year to Forget for Pfizer Inc.
The S&P 500 index soared 19% in 2017 (so far). The healthcare sector performed even better, with year-to-date gains of close to 21%.
Pfizer Inc.: Earnings Double Thanks to Prevnar Sales
Johnson & Johnson (JNJ) Presents at BMO Capital Markets Prescriptions for ...
Everybody thank you so much for joining us today. We're moving on to our second presentation, which is Johnson & Johnson. And I think Lisa is going to read some disclosures.
What to Expect From AbbVie Inc. in 2018
Early this year, I bought a position in AbbVie (NYSE:ABBV). The big pharma stock is on track for 2017 to be its best year ever. And I'm sitting on a nice gain of 57%, a little higher than AbbVie's year-to-date gain because of the timing of when I ...
Checking the Overall Picture for AbbVie Inc. (ABBV)  StockNewsJournal
Now Offering Discount Or Premium? – AbbVie Inc. (ABBV), Globalstar, Inc ...  Post Analyst
Johnson & Johnson, Sanofi top 'Good Pharma' trial transparency ranking with ...
Bioethics International's latest study of clinical transparency for new drugs studied meds approved by the FDA in 2014. Share Facebook Twitter LinkedIn Email Print.